Pfizer (NYSE:PFE) Stock Price Down 0.1%

Pfizer Inc. (NYSE:PFE - Get Free Report)'s share price fell 0.1% during trading on Friday . The company traded as low as $27.72 and last traded at $27.75. 40,466,657 shares traded hands during trading, a decline of 15% from the average session volume of 47,662,984 shares. The stock had previously closed at $27.78.

Analysts Set New Price Targets

A number of brokerages recently commented on PFE. TD Cowen lowered Pfizer from an "outperform" rating to a "market perform" rating and set a $32.00 price target on the stock. in a report on Thursday, January 4th. Guggenheim started coverage on Pfizer in a research note on Friday, February 23rd. They issued a "buy" rating and a $36.00 target price on the stock. UBS Group lowered their target price on Pfizer from $34.00 to $27.00 and set a "neutral" rating on the stock in a research note on Thursday, December 14th. Argus lowered Pfizer from a "buy" rating to a "hold" rating in a research note on Friday, March 22nd. Finally, Truist Financial lowered their target price on Pfizer from $42.00 to $36.00 and set a "buy" rating on the stock in a research note on Thursday, December 14th. Twelve research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat, the company has an average rating of "Hold" and an average target price of $36.88.

Pfizer Price Performance

The business has a 50-day simple moving average of $27.45 and a 200 day simple moving average of $29.45. The firm has a market cap of $157.14 billion, a P/E ratio of 77.08, a price-to-earnings-growth ratio of 1.24 and a beta of 0.61. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.91.

Pfizer (NYSE:PFE - Get Free Report) last released its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, beating analysts' consensus estimates of ($0.19) by $0.29. The company had revenue of $14.25 billion during the quarter, compared to analysts' expectations of $14.37 billion. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The firm's revenue for the quarter was down 41.3% compared to the same quarter last year. During the same quarter last year, the business posted $1.14 EPS. On average, analysts anticipate that Pfizer Inc. will post 2.22 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Newbridge Financial Services Group Inc. increased its holdings in shares of Pfizer by 19.1% in the 4th quarter. Newbridge Financial Services Group Inc. now owns 17,275 shares of the biopharmaceutical company's stock worth $497,000 after purchasing an additional 2,769 shares in the last quarter. HighPoint Advisor Group LLC bought a new stake in shares of Pfizer in the 4th quarter worth $5,135,000. Fairman Group LLC bought a new stake in shares of Pfizer in the 4th quarter worth $84,000. Napatree Capital LLC bought a new stake in shares of Pfizer in the 4th quarter worth $729,000. Finally, Livelsberger Financial Advisory bought a new stake in shares of Pfizer in the fourth quarter worth $118,000. Institutional investors own 68.36% of the company's stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.